---
title: "BETTA PHARMACEUTICALS: Currently, there is no need to provision for the issuance loss of Heyuan Biotechnology"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/254297503.md"
description: "An investor asked BETTA PHARMACEUTICALS: The issuance time of HeYuan has exceeded the expected time and is expected to be unable to issue. Please clarify the specific loss costs. In response, BETTA PHARMACEUTICALS replied on August 24th on the interactive platform that the China Securities Regulatory Commission has approved the registration application for the initial public offering of Wuhan HeYuan Biotechnology Co., Ltd. For specific issuance information, please pay attention to the public information disclosure of HeYuan Biotechnology. Currently, the company does not need to recognize any losses"
datetime: "2025-08-24T06:50:42.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/254297503.md)
  - [en](https://longbridge.com/en/news/254297503.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/254297503.md)
generator: "portal-rs"
---

# BETTA PHARMACEUTICALS: Currently, there is no need to provision for the issuance loss of Heyuan Biotechnology

An investor asked Betta Pharmaceuticals: The issuance time of Heyuan has exceeded the expected time and is expected to be unable to issue. Please clarify the specific loss costs. In response, Betta Pharmaceuticals replied on the interactive platform on August 24th that the China Securities Regulatory Commission has approved the registration application for the initial public offering of Wuhan Heyuan Biotechnology Co., Ltd. For specific issuance information, please pay attention to the public information disclosure of Heyuan Biotechnology. Currently, the company does not need to recognize any losses

### Related Stocks

- [300558.CN](https://longbridge.com/en/quote/300558.CN.md)
- [0BDYY.HK](https://longbridge.com/en/quote/0BDYY.HK.md)

## Related News & Research

- [Bessent's bond gambit aimed at calming markets is instead stirring inflation worries](https://longbridge.com/en/news/296642975.md)
- [Trump’s Bond Buyback Push Puts Kevin Warsh in a Tough Spot — Peter Schiff Says Treasury ‘Pulled the Rug Out From Under’](https://longbridge.com/en/news/296615127.md)
- [Scott Bessent Brings His Hedge Fund Playbook To Treasury. The Bond Market Is Fighting Back](https://longbridge.com/en/news/296520391.md)
- [Novo Nordisk Stock And 2 Dividend Growers With Strong Cash Flow](https://longbridge.com/en/news/296635949.md)
- [Livzon Pharma buys 3.5% Xinbeijiang Pharma stake for RMB 106.7 million](https://longbridge.com/en/news/296601614.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**